CIA
RCUS icon

Cape Investment Advisory’s Arcus Biosciences RCUS Stock Holding History

Cape Investment Advisory’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-4,045
Closed -$77.3K – 1125
2023
Q4 		$77.3K Buy
+4,045
New +$64.6K 0.04% 277

Other funds holding RCUS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Cape Investment Advisory's RCUS Position: Q1 2024 in Review

Cape Investment Advisory sold out of Arcus Biosciences (RCUS) in Q1 2024, closing a stake of 4,045 shares — an estimated $77.3K sold.

Cape Investment Advisory first reported a position in RCUS in Q4 2023 and held it in 1 quarter. The position peaked at $77.3K in Q4 2023. 172 funds tracked by Wall St. Rank hold RCUS as of Q1 2024.

  • Cape Investment Advisory reported no remaining Arcus Biosciences position as of Q1 2024 after selling out during the quarter.
  • Cape Investment Advisory sold 4,045 Arcus Biosciences shares in Q1 2024, an estimated $77.3K.
  • Cape Investment Advisory first reported a position in Arcus Biosciences in Q4 2023 and held it in 1 quarter.
  • Cape Investment Advisory's Arcus Biosciences position peaked at $77.3K in Q4 2023.
  • 172 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2024.

Based on Cape Investment Advisory's 13F filing for Q1 2024, filed 21 Jun 2024.